Published in Biotech Business Week, October 25th, 2004
The 8-month study will determine the efficacy and ability of the company's proprietary AastromReplicell System to enhance the immunostimulatory potency of dendritic cell-based cancer vaccines through its patented Single-Pass Perfusion technology. The principal investigator in the study is Douglas M. Smith, PhD, Immunology Program leader at Aastrom.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.